No Clear Survival Benefit for Fulvestrant Versus Letrozole in Combination With Palbociclib for Endocrine-Sensitive Metastatic Breast Cancer
Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study - ScienceDirect
Current Oncology | Free Full-Text | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABC - YouTube
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy - Tam Binh V Bui, Desirée MT Burgers, Mariette J Agterof, Ewoudt
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
View PDF
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: An observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
